Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAmework-01: Sofetabart Mipitecan in Platinum-Resistant and Platinum-Sensitive Ovarian Cancer
jRCT2011250060Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of sofetabart mipitecan in High-Grade Serous Ovarian Cancer (HGSOC), Endometrioid Cystadenocarcinoma, primary peritoneal cancer (PPC) and 2 more (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free Survival (PFS). Started Feb 2026; status: recruiting.
02
Drugs
sofetabart mipitecan
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)Endometrioid Cystadenocarcinomaprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)metastasis
Beyond the preview
Go deeper on jRCT2011250060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250060.